In 2018, double digit growth for prioritized brands Opdivo, which grew by $443 million, Eliquis, which grew by $342 million, Yervoy, which grew by $115 million, as well as Orencia, helped to offset significant declines in established brands
Baraclude, Reyataz, Sustiva, and Hepatitis C franchises (for which revenues have all but disappeared), representing a total of $1.5 billion in lost revenue as compared to 2017.
Hoffmann-La Roche Ltd., Basel, Switzerland) 180 [micro]g once weekly for 48 weeks and sequential treatment groups (ETV;
Baraclude, Bristol-Myers Squibb, New York, USA) 0.5 mg once daily for 4 weeks followed by a combination of ETV and Pegasys (for 8 weeks), followed by Pegasys alone (for 40 weeks).
M2 PHARMA-March 28, 2018-Breckenridge Pharmaceutical wins final US FDA approval for Entecavir tablets (
Baraclude) ANDA for hepatitis B infection
M2 EQUITYBITES-March 28, 2018-Breckenridge Pharmaceutical wins final US FDA approval for Entecavir tablets (
Baraclude) ANDA for hepatitis B infection
A dose of 0.5mg entecavir (
Baraclude; Bristol-Myers Squibb, New York, USA) was administered daily even after the introduction of add-on PEG-IFNa-2a treatment.
Globally, the hepatitis B therapeutics market is served moderately well by the available products, of which
Baraclude and Viread are the most frequently prescribed.
Entecavir is a generic version of
Baraclude tablets (0.5 mg and 1 mg) from Bristol-Myers Squibb.
* Entecavir (
Baraclude): A pill taken once a day for one year or longer.
Loss of the hepatitis B e antigen (HBeAg) and hepatitis B viral (HBV) DNA levels below 200 IU / mL after 48 weeks of therapy occurred in 18% of patients randomized to entecavir (
Baraclude) and pegylated interferon alfa-2a (Pegasys), vs.
In 2011, only two blockbusters existed in the market -
Baraclude for treating hepatitis B and Incivek for treating hepatitis C.
CS (OS) 534/2010], a suit filed for the permanent injunction restraining the defendant from infringing the patent IN213457 in respect of the drug "
Baraclude", the Delhi High Court refused to grant the interim injunction to Bristol-Myers Squibb (BMS) on the ground that patent in suit is a product by process patent and not a pure product patent.